Trifarotene
- Generic Name
- Trifarotene
- Brand Names
- Aklief
- Drug Type
- Small Molecule
- Chemical Formula
- C29H33NO4
- CAS Number
- 895542-09-3
- Unique Ingredient Identifier
- 0J8RN2W0HK
Overview
Trifarotene is a topical retinoid cream used in the treatment of acne vulgaris that was first approved for use in the United States in October 2019. Retinoids are a class of medications structurally and functionally analogous to vitamin A, though later generation retinoids such as trifarotene and adapalene bear little structural resemblance to vitamin A and are analogous only in function. Trifarotene is considered the first of the "fourth-generation" retinoids due to its uniquely selective activity - this selectivity appears to confer improved efficacy and reduced side effects as compared to older, less selective retinoids.
Background
Trifarotene is a topical retinoid cream used in the treatment of acne vulgaris that was first approved for use in the United States in October 2019. Retinoids are a class of medications structurally and functionally analogous to vitamin A, though later generation retinoids such as trifarotene and adapalene bear little structural resemblance to vitamin A and are analogous only in function. Trifarotene is considered the first of the "fourth-generation" retinoids due to its uniquely selective activity - this selectivity appears to confer improved efficacy and reduced side effects as compared to older, less selective retinoids.
Indication
Trifarotene is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.
Associated Conditions
- Acne Vulgaris
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2024/12/13 | Phase 1 | Completed | |||
2023/10/02 | Phase 1 | Completed | |||
2022/09/22 | Phase 3 | Completed | |||
2021/10/22 | Phase 4 | Completed | |||
2021/04/23 | Phase 4 | Completed | |||
2020/06/30 | Phase 4 | Completed | |||
2019/04/16 | Phase 3 | Completed |
FDA Approved Products
Product Name | Manufacturer | Route | Strength | Approved | NDC Code |
|---|---|---|---|---|---|
AKLIEF | TOPICAL | 50 ug in 1 g | 2024/01/25 | 0299-5935 |
EMA Approved Products
Medicine Name | EMA Number | Auth. Holder | Country | Drug Type | Status | Issued | Opinion | Revision |
|---|
No EMA products found
No EMA products found for this drug
Singapore Approved Products
Product Name | Manufacturer | Dosage Form | Strength | Approved | Approval No. |
|---|---|---|---|---|---|
AKLIEF CREAM 50mcg/g | CREAM | 50 mcg/g | 2022/08/17 | SIN16571P |
China Approved Products
Product Name | Approval No. | Manufacturer | Dosage Form | Trade Name | Strength | Type | Status | Date | Import |
|---|
No China products found
No China products found for this drug
Australia Approved Products
Product Name | ARTG ID | Sponsor | Status | Reg. Date | Ingredient |
|---|---|---|---|---|---|
AKLIEF trifarotene 50 microgram/g cream tube | 340375 | Active | 2021/01/18 | trifarotene | |
AKLIEF trifarotene 50 microgram/g cream bottle | 332220 | Active | 2021/01/18 | trifarotene |